Diversified Trust Co Decreases Stock Position in Axonics, Inc. (NASDAQ:AXNX)

Diversified Trust Co cut its stake in shares of Axonics, Inc. (NASDAQ:AXNX) by 41.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,642 shares of the company’s stock after selling 5,325 shares during the quarter. Diversified Trust Co’s holdings in Axonics were worth $527,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Principal Financial Group Inc. increased its position in shares of Axonics by 461.1% in the fourth quarter. Principal Financial Group Inc. now owns 65,668 shares of the company’s stock valued at $4,087,000 after acquiring an additional 53,965 shares during the period. Stratos Wealth Partners LTD. bought a new position in Axonics during the 4th quarter valued at approximately $1,298,000. Artisan Partners Limited Partnership raised its position in Axonics by 91.7% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,220,889 shares of the company’s stock valued at $75,976,000 after purchasing an additional 583,958 shares during the last quarter. Lisanti Capital Growth LLC lifted its holdings in Axonics by 41.6% in the 4th quarter. Lisanti Capital Growth LLC now owns 106,950 shares of the company’s stock worth $6,655,000 after buying an additional 31,400 shares during the period. Finally, Hsbc Holdings PLC grew its position in shares of Axonics by 26.5% in the 4th quarter. Hsbc Holdings PLC now owns 65,494 shares of the company’s stock worth $4,076,000 after buying an additional 13,734 shares during the last quarter. 99.48% of the stock is currently owned by institutional investors.

Axonics Price Performance

Shares of Axonics stock opened at $67.52 on Thursday. Axonics, Inc. has a 1 year low of $48.02 and a 1 year high of $69.68. The firm has a market cap of $3.44 billion, a price-to-earnings ratio of -211.00 and a beta of 0.83. The company has a 50-day moving average of $67.27 and a 200 day moving average of $66.98.

Axonics (NASDAQ:AXNX) last announced its earnings results on Tuesday, April 30th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.32). Axonics had a negative net margin of 4.12% and a negative return on equity of 2.58%. The business had revenue of $91.41 million for the quarter, compared to the consensus estimate of $89.79 million. During the same period in the prior year, the business posted ($0.19) EPS. Axonics’s revenue for the quarter was up 29.4% on a year-over-year basis. On average, equities analysts anticipate that Axonics, Inc. will post 0.13 EPS for the current year.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a “hold” rating on shares of Axonics in a report on Monday, May 6th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Axonics has a consensus rating of “Hold” and an average price target of $70.30.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.